Auxiliary partial liver transplantation for acute liver failure using "high risk" grafts: Case report

World J Gastroenterol. 2016 Feb 7;22(5):1919-24. doi: 10.3748/wjg.v22.i5.1919.

Abstract

Acute liver failure (ALF) is a reversible disorder that is associated with an abrupt loss of hepatic mass, rapidly progressive encephalopathy and devastating complications. Despite its high mortality, an emergency liver transplantation nowadays forms an integral part in ALF management and has substantially improved the outcomes of ALF. Here, we report the case of a 32-year-old female patient who was admitted with grade IV hepatic encephalopathy (coma) following drug-induced ALF. We performed an emergency auxiliary partial orthotopic liver transplantation with a "high risk" graft (liver macrovesicular steatosis approximately 40%) from a living donor. The patient was discharged on postoperative day 57 with normal liver function. Weaning from immunosuppression was achieved 9 mo after transplantation. A follow-up using CT scan showed a remarkable increase in native liver volume and gradual loss of the graft. More than 6 years after the transplantation, the female now has a 4-year-old child and has returned to work full-time without any neurological sequelae.

Keywords: Acute liver failure; Auxiliary partial orthotopic liver transplantation; Fatty liver graft.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biopsy
  • Chemical and Drug Induced Liver Injury / diagnosis
  • Chemical and Drug Induced Liver Injury / etiology
  • Chemical and Drug Induced Liver Injury / surgery*
  • Donor Selection*
  • Fatty Liver / complications
  • Fatty Liver / diagnosis
  • Female
  • Graft Survival
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Liver Failure, Acute / chemically induced
  • Liver Failure, Acute / diagnosis
  • Liver Failure, Acute / surgery*
  • Liver Function Tests
  • Liver Regeneration*
  • Liver Transplantation / adverse effects
  • Liver Transplantation / methods*
  • Living Donors*
  • Risk Factors
  • Time Factors
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Immunosuppressive Agents